News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
10/27/16StemCells, Inc. Encourages Stockholders to Return Proxies Approving the Microbot Merger by November 14, 2016
Four of Five Proposals Approved at Company’s 2016 Special Stockholder Meeting NEWARK, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM) reported today that four of the five proposals presented at the stockholder meeting in connection with the Company’s planned merger transaction with Microbot Medical Ltd. (Microbot) were approved yesterday.  The first proposal – to approve and adopt the Agreement and Plan of Merger and Reorganization with Microbot – was not taken up for ... 
Printer Friendly Version
08/16/16StemCells, Inc. and Microbot Medical Ltd. Announce Strategic Merger
Companies Plan to Pursue Development of Robotics Based Medical Devices for the Treatment of Cerebrospinal Fluid and Gastrointestinal Disorders, as Well as Other Conditions NEWARK, Calif. and YOKNEAM, Israel, Aug. 16, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM) and Microbot Medical Ltd., a private company organized under the laws of the State of Israel (“Microbot”), today announced that they have entered into a definitive merger agreement, with plans to pursue the development of rob... 
Printer Friendly Version
05/31/16StemCells, Inc. Announces Termination of Phase II Pathway Study Following Review of Data
Company to Commence Orderly Wind Down of Operations NEWARK, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM) (the “Company”) today announced its decision to terminate the Company’s Phase II Pathway Study in spinal cord injury following an in-depth review of data from the study and after obtaining the concurrence of the study’s Interim Analysis Data Monitoring Committee (the “IA-DMC”).  While the results showed overall improvement in patients treated with the Company’s pr... 
Printer Friendly Version
05/10/16StemCells, Inc. to Report 12-Month Cohort I Data from its Phase II Pathway Study
NEWARK, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a leading stem cell company developing novel cell-based therapeutics for the treatment of serious central nervous system diseases, today announced that it will be presenting top line 12-month data from Cohort I of its Pathway™ Study later this month as part of the Company’s first quarter 2016 analyst call. The Company is planning to then release detailed final data on Cohort I at a scientific venue in June. The ... 
Printer Friendly Version
05/06/16StemCells, Inc. Announces 1-for-12 Reverse Stock Split
NEWARK, Calif., May 06, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM),  announced today that at its annual stockholders meeting held on May 5, 2016, the Company's stockholders voted to approve a reverse stock split of the Company's common stock at a ratio of 1-for-12. Trading of the Company's common stock on the NASDAQ Capital Market will continue, on a split-adjusted basis, with the opening of the markets on Monday, May 9, 2016, under the existing trading symbol "STEM" and a new CUSI... 
Printer Friendly Version
04/27/16StemCells, Inc. to Participate in the 3rd Annual Growth Capital Expo MicroCap Investor Conference in Las Vegas, NV
NEWARK, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will make a presentation on the Company's programs, pipeline and operations at the 3rd Annual Growth Capital Expo MicroCap Investor Conference, held May 3 – 5, 2016 at Caesars Palace in Las Vegas, NV. The Company will be presenting at 11:00 a.m. Pacific Daylight Time on Wednesday, May 4. A live webcast of the presentation will be available through the Company's corporate website:... 
Printer Friendly Version
04/18/16StemCells, Inc. Presents Interim Results from its Phase II Pathway Study in Chronic Cervical Spinal Cord Injury at ASIA Annual Meeting
Final Results for the First Six Patients to be Released Later this Quarter NEWARK, Calif., April 18, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system disorders, announced today that Dr. Stephen Huhn, the Company’s Chief Medical Officer and VP of Clinical Research, presented additional details on its ongoing Phase II Pathway™ Study of HuCNS-SC cells for the treatment of ... 
Printer Friendly Version
03/30/16StemCells, Inc., Pathway™ Study in Cervical Spinal Cord Injury Featured in The Downey Patriot
NEWARK, Calif., March 30, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system disorders, today announced the company’s ongoing Phase II Pathway™ Study in cervical spinal cord injury (SCI) was featured in an article published in The Downey Patriot. For the story entitled “Rancho Los Amigos partners with USC for groundbreaking stem cell research,” Christian Brown spoke wit... 
Printer Friendly Version
03/23/16StemCells, Inc. Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update
Conference Call to be Hosted March 24, 2016, at 5:00 a.m. Pacific Daylight Time (8:00 a.m. Eastern Daylight Time) NEWARK, Calif., March 23, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a leading stem cell company developing novel cell-based therapeutics for the treatment of serious central nervous system diseases, announced today that it will provide a business update and discuss financial results for the fourth quarter and year ended December 31, 2015, tomorrow, March 24, at 5:00 ... 
Printer Friendly Version
03/21/16StemCells, Inc. Announces Updated Timing for Webcast to Discuss Fourth Quarter 2015 Financial Results
NEWARK, Calif., March 21, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for the treatment of serious central nervous system diseases, announced today that it will host a conference call and webcast to discuss its results and an update on its business at 5:00 a.m. Pacific Daylight Time (8:00 a.m. Eastern Daylight Time) March 24. Interested parties are invited to listen to the call over the Internet by accessing the ... 
Printer Friendly Version
03/15/16StemCells, Inc. Announces Webcast to Discuss Fourth Quarter 2015 Financial Results
NEWARK, Calif., March 15, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for the treatment of serious central nervous system diseases, announced today that it will host a conference call and webcast to discuss its results and an update on its business at 1:30 p.m. Pacific Daylight Time (4:30 p.m. Eastern Daylight Time) March 23. Interested parties are invited to listen to the call over the Internet by accessing th... 
Printer Friendly Version
03/14/16StemCells, Inc. Announces Closing of $8 Million Public Offering
NEWARK, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM) today announced that it has closed its previously announced offering of common stock and warrants. The Company sold a total of 26,667,000 shares of common stock, Series A warrants to purchase up to 13,333,500 shares of the Company’s common stock, and Series B warrants to purchase up to 20,000,250 shares of the Company’s common stock, at a public offering price of approximately $8 million. In addition, pursuant to ... 
Printer Friendly Version
03/09/16StemCells, Inc. Announces Pricing of Public Offering to Raise $8.1 Million
NEWARK, Calif., March 09, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM) today announced the pricing of an underwritten public offering of common stock, Series A Warrants and Series B Warrants with a public offering price of $0.30 for one share, a Series A Warrant to purchase 0.50 of a share of common stock and a Series B Warrant to purchase 0.75 of a share of common stock. The Company expects to receive gross proceeds of approximately $8.1 million, before deducting underwriting discou... 
Printer Friendly Version
03/08/16StemCells, Inc. Announces Proposed Public Offering of Common Stock and Warrants
NEWARK, Calif., March 08, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM) today announced that it intends to offer and sell common stock, Series A Warrants and Series B Warrants, subject to market and other conditions, in an underwritten public offering. The common stock, Series A Warrants and Series B Warrants are being offered under the Company’s effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC).  The Company plans to file a regi... 
Printer Friendly Version
02/26/16StemCells, Inc., Pathway™ Study in Cervical Spinal Cord Injury Featured in Pittsburgh Post-Gazette
NEWARK, Calif., Feb. 26, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system disorders, today announced the company’s ongoing Phase II Pathway™ Study in cervical spinal cord injury (SCI) was featured in an article published in the Pittsburgh Post-Gazette. ... 
Printer Friendly Version
02/04/16Ian Massey, President and CEO of StemCells, Inc., to Participate on a Regenerative Medicine Panel at Source Capital Group’s 2016 Disruptive Growth and Healthcare Conference
NEWARK, Calif., Feb. 04, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Ian Massey, President and CEO of StemCells, Inc., will participate on a regenerative medicine panel at Source Capital Group’s 2016 Disruptive Growth and Healthcare Conference. The panel will take place on Feb. 10, at 1:30 p.m., Eastern Standard Time, at the Convene Conference Center, 730 3rd Avenue, in New York City. The panel will be moderated by Todd Fromer, principal of KCSA Strategic Commun... 
Printer Friendly Version
01/28/16StemCells, Inc. to Participate at the 2016 BIO CEO Conference and Source Capital Group’s 2016 Disruptive Growth and Healthcare Conference
StemCells, Inc. Was Voted the 2016 Winner “Buzz of BIO” Public Company NEWARK, Calif., Jan. 28, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will make presentations on the Company's programs, pipeline and operations at two upcoming conferences in February. The Company will be presenting at the 2016 BIO CEO Conference on Feb. 8 at 2:30 p.m. Eastern Standard Time at the Waldorf Astoria in New York City. StemCells, Inc. was recognized as the most inno... 
Printer Friendly Version
01/11/16StemCells, Inc. CEO Martin McGlynn Passes Baton to President and COO Ian Massey
Experienced Biotech Leader to Become Next Chief Executive Officer NEWARK, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system disorders, today announced that Dr. Ian Massey, its President and Chief Operating Officer, has been appointed by the Board of Directors to succeed Martin McGlynn as the Company’s Chief Executive Officer, effective January 18, 2016. ... 
Printer Friendly Version
01/06/16StemCells, Inc. to Participate at the 8th Annual Biotech Showcase Investor Conference
Management Will Present an Update on the Company’s Programs, Pipeline and Operations NEWARK, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will make a presentation on the Company's programs, pipeline and operations at the 8th Annual Biotech Showcase Investor Conference.  Management is scheduled to speak at 4:30 p.m. Pacific Standard Time on Monday, January 11, at the Parc 55 Hotel, located at 55 Cyril Magnin Street, San Francisco. A... 
Printer Friendly Version
12/23/15StemCells, Inc. Announces Strategic Realignment
Prioritizes Spinal Cord Injury Program to Reduce Cash Needs and Expedite Progress to Pivotal Data NEWARK, Calif., Dec. 23, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, today announced a strategic realignment to fully focus the Company’s resources on its proprietary HuCNS-SC® platform technology for the treatment of chronic spinal cord injury (SCI).... 
Printer Friendly Version
11/18/15StemCells, Inc. Interim Trial Data Show Motor Improvement in Patients With Cervical Spinal Cord Injury
Positive Six-Month Results, With Gains in Both Strength and Motor Function, for the First Cohort in the Phase II Pathway Study NEWARK, Calif., Nov. 18, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, today announced that the six-month interim results for the first cohort in its ongoing Phase II Pathway™ Study in cervical spinal cord injury (SCI) showe... 
Printer Friendly Version
11/12/15StemCells, Inc. Announces Webcast to Discuss Interim Results From the First Cohort in Its Phase II Study in Cervical Spinal Cord Injury
NEWARK, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, will host a webcast to discuss the six-month interim results from the first cohort in its Phase II PathwayTM Study in cervical spinal cord injury. The Company will also provide a progress update on the second 40-patient cohort which is currently enrolling patients. The first co... 
Printer Friendly Version
11/02/15StemCells, Inc. Reports Third Quarter 2015 Financial Results
Company to Host Call to Provide Interim Results from the First Cohort in its Phase II Pathway™ Study in Cervical Spinal Cord Injury NEWARK, Calif., Nov. 02, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, today reported its financial and operating results for the three months ended September 30, 2015. “We continue to advance our HuCNS-SC® human neu... 
Printer Friendly Version
08/26/15StemCells, Inc. to Participate at the Rodman & Renshaw 17th Annual Global Investment Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., Aug. 26, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will make a presentation on the Company's programs, pipeline and operations at the Rodman & Renshaw 17th Annual Global Investment Conference. Management is scheduled to speak at 1:45 p.m. Eastern Standard Time on Wednesday, September 9, at the St. Regis Hotel, located at Two East 55th Street in Ne... 
Printer Friendly Version
08/06/15StemCells, Inc. Reports Second Quarter 2015 Financial Results, Business Update and Clinical Program Highlights
Conference Call August 6, 2015, at 4:30 PM EDT (1:30 PM PDT) Including New Information About Phase I/II AMD Trial Results NEWARK, Calif., Aug. 6, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, today reported its financial results for the three months ended June 30, 2015. The Company also provided a business update and clinical program highlights for th... 
Printer Friendly Version
07/23/15Court Rules That StemCells, Inc. Lacks Standing to Pursue Patent Infringement Suit
NEWARK, Calif., July 23, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, announced today that the Company's patent infringement case, StemCells, Inc. v. Neuralstem, Inc., has been dismissed by the U.S. Federal District Court for the District of Maryland for lack of standing. The judge's decision was based solely on the grounds that a former associate of ... 
Printer Friendly Version
07/22/15StemCells, Inc. Announces Webcast to Discuss Second Quarter 2015 Financial Results
NEWARK, Calf., July 22, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the second quarter 2015, after the market close on Thursday, August 6. StemCells will host a conference call and webcast to discuss its results and an update on its business at 1:30 p.m. Pacific Daylight Ti... 
Printer Friendly Version
07/20/15StemCells, Inc. Transplants First Patient in Phase II Clinical Trial for Dry Age-Related Macular Degeneration
Radiant(TM) Study is the First Controlled Phase II Trial to Investigate the Efficacy of Human Neural Stem Cells for the Treatment of Dry AMD NEWARK, Calif., July 20, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the brain, eye and spine, announced today that it has completed transplantation of the first subject in its Radiant Study at the Retina Foundation of the Southwest. The ... 
Printer Friendly Version
07/09/15StemCells, Inc. Clinical Programs Overview and Progress Update
Video Available of Presentation Made to World-Leading Scientists and Clinicians at the International Society for Stem Cell Research (ISSCR) NEWARK, Calif., July 9, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), in cooperation with the International Society for Stem Cell Research (ISSCR), has posted a video of the presentation made by the Company's vice president of clinical research and chief medical officer Dr. Stephen Huhn, at the ISSCR 2015 Annual Meeting. Held last month in Stockho... 
Printer Friendly Version
07/01/15StemCells, Inc. to Participate at Cantor Fitzgerald's Inaugural Healthcare Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., July 1, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will make a presentation on the Company's programs, pipeline and operations at Cantor Fitzgerald's Inaugural Healthcare Conference. Management is scheduled to speak at 11:45 a.m. Eastern Standard Time on Wednesday, July 8, at the Le Parker Meridian Hotel, located at 119 W. 56th Street in New York City.... 
Printer Friendly Version
06/26/15StemCells, Inc. Reports Top Line Results for Its Phase I/II Study in Dry Age Related Macular Degeneration
Initiates Phase II Proof-of-Concept Radiant(TM) Study in AMD NEWARK, Calif., June 26, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a leading stem cell company developing novel cell-based therapeutics for treating diseases and disorders of the central nervous system, announced today that Dr. Stephen Huhn, its Vice President of Clinical Research and Chief Medical Officer, presented an overview of the Company's clinical translation efforts to date, including a summary of the safety and ... 
Printer Friendly Version
06/18/15StemCells, Inc.'s Phase II Pathway Study for Cervical Spinal Cord Injury Approved by Health Canada
NEWARK, Calif., June 18, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system diseases and disorders, announced today that Health Canada has authorized the Company to expand its Phase II clinical trial for chronic cervical spinal cord injury into Canada. The Pathway Study™ is designed to assess the efficacy of the Company's proprietary HuCNS-SC® platform technology (purified h... 
Printer Friendly Version
06/04/15StemCells, Inc. Announces Commencement of the Second Cohort of the Pathway(TM) Study in Cervical Spinal Cord Injury
Phase II Study Designed to Assess the Potential of Human Neural Stem Cells to Restore Motor Function NEWARK, Calif., June 4, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system diseases and disorders, announced today that it has enrolled its first subject in Cohort 2 of its Phase II Pathway Study. The study is designed to assess the efficacy of the Company's proprietary HuCN... 
Printer Friendly Version
06/01/15StemCells, Inc. Announces Closing of Over-Allotment Option
NEWARK, Calif., June 1, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that the underwriters of the Company's public offering that initially closed on April 29, 2015 have purchased an additional 2,757,250 shares of the Company's common stock at a price of $0.699 per share, before the underwriting discount, in connection with the exercise of their option to purchase additional shares of common stock (the "Over-Allotment Option"). The Company received additional net proceed... 
Printer Friendly Version
05/18/15StemCells, Inc. to Participate at the 2015 Marcum MicroCap Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., May 18, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will make a presentation on the Company's programs, pipeline and operations at the 2015 Marcum MicroCap Conference. Management is scheduled to speak at 1:30 p.m. Eastern Daylight Time on Thursday, May 28, at The Grand Hyatt New York Hotel, in the Imperial room, located at 109 E 42nd Street in New York ... 
Printer Friendly Version
05/14/15StemCells, Inc. Announces Positive Top-Line Results of Its Thoracic Spinal Cord Injury Phase I/II Study
Sensory gains demonstrate the clinical effect of HuCNS–SC® transplantation Results hold promise for Phase II PathwayTM cervical spinal cord injury study NEWARK, Calif., May 14, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for treating diseases of the central nervous system, announced today that Dr. Armin Curt, principal investigator, will present a summary of the safety and preliminary efficacy data from the ... 
Printer Friendly Version
05/05/15StemCells, Inc. Reports First Quarter 2015 Financial Results and Provides Business Update
Conference Call to be Hosted May 5, 2015, at 4:30PM EDT (1:30 PM PDT) NEWARK, Calif., May 5, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics for diseases of the central nervous system, today provided a business update and reported financial results for the first quarter 2015. "StemCells, Inc. continues to make great progress," said Martin McGlynn, CEO of StemCells, Inc. "We have completed the en... 
Printer Friendly Version
04/30/15StemCells, Inc. Announces Webcast to Discuss First Quarter 2015 Financial Results
NEWARK, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the first quarter 2015, after the market close on Tuesday, May 5. StemCells will host a conference call and webcast to discuss its results and an update on its business at 1:30 p.m. Pacific Daylight Time ... 
Printer Friendly Version
04/29/15StemCells, Inc. Announces Closing of $25 Million Public Offering
NEWARK, Calif., April 29, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it has closed its previously announced offering of common stock and warrants. The Company sold a total of 35,715,000 shares and warrants to acquire 26,786,250 shares of common stock at a public offering price of $0.70 per unit for a fixed combination of one share of common stock and a warrant to purchase three-quarters of a share of common stock. The Company also issued warrants to purchase an a... 
Printer Friendly Version
04/27/15StemCells, Inc. to Participate at the Inaugural World Medical Innovation Forum
CEO Martin McGlynn Will Participate on the "Regeneration, Cell Therapy, and Neurocare: Products? Delivery?" Panel NEWARK, Calif., April 27, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Martin McGlynn, CEO of StemCells, Inc., will participate on a panel moderated by Alice Park, writer for TIME Magazine, at the inaugural World Medical Innovation Forum to be held in Boston, April 27-29, 2015. The expert panel members will discuss central nervous system therapies that... 
Printer Friendly Version
04/24/15StemCells, Inc. Announces Pricing of Public Offering to Raise $25 Million
NEWARK, Calif., April 24, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the pricing of an underwritten public offering of common stock and warrants with a public offering price of $0.70 for a fixed combination of one share of common stock and a warrant to purchase three-quarters of a share of common stock. The warrants have an exercise price of $0.85 per share, are exercisable immediately, and will expire five years from the date of issuance. The Company expects to recei... 
Printer Friendly Version
04/23/15StemCells, Inc. Announces Proposed Public Offering of Common Stock and Warrants
NEWARK, Calif., April 23, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritten public offering. The shares and warrants are being offered under the Company's effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). StemCells intends to use the net proceeds of the offering for general corporate purposes, includi... 
Printer Friendly Version
04/16/15StemCells, Inc. Completes Enrollment of First Cohort in Phase II Pathway Study for Cervical Spinal Cord Injury
Proof-of-Concept Study Designed to Measure Improvement in Motor Function NEWARK, Calif., April 16, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for treating diseases of the central nervous system with high unmet medical need, announced today that it has completed transplanting the six patients comprising the first cohort of its Phase II Pathway® Study. The first cohort is an open-label dose escalation arm to determi... 
Printer Friendly Version
04/07/15StemCells, Inc. to Participate at the 14th Annual Needham Healthcare Conference
CEO Martin McGlynn Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., April 7, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Martin McGlynn, CEO of StemCells, Inc., will make a presentation on the Company's programs and operations at the 14th Annual Needham Healthcare Conference. Management is scheduled to speak at 3:40 p.m. Eastern Daylight Time on Wednesday, April 15, at The Westin NY Grand Central Hotel located at 212 E 42n... 
Printer Friendly Version
03/24/15StemCells, Inc. Appoints Ian Massey as President and Chief Operating Officer
NEWARK, Calif., March 24, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, today announced that Ian Massey, D. Phil., has joined its executive team as President and Chief Operating Officer, effective March 23, 2015. In this new role, Dr. Massey has direct responsibility for all aspects of the Company's research and development, manufacturing, regulatory affairs, and quality as... 
Printer Friendly Version
03/16/15StemCells, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business Update
Conference Call to be Hosted March 16, 2015 at 4:30 p.m. EDT (1:30 PM PDT) NEWARK, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics for diseases of the central nervous system, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2014. "We achieved three significant clinical translation milestones in 2014: the completi... 
Printer Friendly Version
03/10/15StemCells, Inc. to Participate at the Wall Street Analyst Forum 25th Annual Institutional Investor Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., March 10, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Management will make a presentation on the Company's programs and operations at the Wall Street Analyst Forum 25th Annual Institutional Investor Conference. Management is scheduled to speak at 10:35 a.m. Eastern Daylight Time on Thursday, March 19, at The University Club located at 1 West 54th Street in NYC. ... 
Printer Friendly Version
03/09/15StemCells, Inc. Announces Webcast to Discuss Fourth Quarter and Full Year 2014 Financial Results
NEWARK, Calif., March 9, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the fourth quarter and full year ended December 31, 2014, after the market close on Monday, March 16. StemCells will host a conference call and webcast to discuss its results and an update on its business ... 
Printer Friendly Version
02/05/15Safety and Preliminary Efficacy of Human Neural Stem Cells in StemCells, Inc.'s Dry AMD Study to be Presented at Ophthalmology Conference
NEWARK, Calif., Feb. 5, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, announced today that Theodore Leng, MD, MS, Clinical Assistant Professor of Ophthalmology at the Byers Eye Institute at Stanford, Stanford University School of Medicine and a principal investigator on StemCells, Inc.'s Phase I/II study in dry age related macular degeneration will be presenting findings on... 
Printer Friendly Version
02/02/15StemCells, Inc. to Participate at the 17th Annual BIO CEO & Investor Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., Feb. 2, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Management will make a presentation on the Company's programs and operations at the 17th Annual BIO CEO & Investor Conference. Management is scheduled to speak at 8:30 a.m. EST on Monday, February 9, at the Waldorf Astoria in New York City. A live webcast of the presentations will be available through the... 
Printer Friendly Version
01/26/15StemCells, Inc. Posts Letter to Shareholders
NEWARK, Calif., Jan. 26, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, posted today the following Letter to Shareholders from its President and CEO, Martin McGlynn. January 26, 2015 Dear Fellow Shareholders: Over the past year, StemCells, Inc. has made substantial progress. We completed enrollment and dosing in our Phase I/II clinical trials in two major indicat... 
Printer Friendly Version
12/18/14StemCells, Inc. Transplants First Participant in Phase II Clinical Trial in Cervical Spinal Cord Injury
Pathway Study to Assess the Potential of Human Neural Stem Cells to Restore Motor Function NEWARK, Calif., Dec. 18, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, announced today that it has transplanted the first subject in its Phase II Pathway® Study assessing the efficacy of its proprietary HuCNS-SC® (purified human neural stem cells) platform techn... 
Printer Friendly Version
12/02/14StemCells, Inc. Hosts Leading Biotech Investors and Analysts at Inaugural Event
NEWARK, Calif., Dec. 2, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leader in the development of cell-based therapies for disorders of the central nervous system (CNS), hosted its first investor and analyst event in New York, on November 20, 2014. The event was well-attended by biotech investing VIPs including representatives from Maxim Group, Piper Jaffray, Brinson Patrick Securities, Needham and Company, H.C. Wainwright and Company, Cantor Fitzgerald, Ladenburg Thalmann and M... 
Printer Friendly Version
11/20/14StemCells, Inc. to Host Inaugural Investor and Analyst Event in New York
NEWARK, Calif., Nov. 20, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), who pioneered the discovery and development of HuCNS-SC® cells, a proprietary population of highly purified, expandable human neural stem cells and is leading the development of cell based therapies for the treatment of disorders of the central nervous system, will host its first investor and analyst event today, November 20, 2014, in New York. The program will feature a keynote address from Irving L. Weissman M... 
Printer Friendly Version
11/05/14StemCells, Inc. Reports Third Quarter 2014 Financial and Operating Results
StemCells, Inc. to Host Investor and Analyst Event in New York, November 20, 2014 NEWARK, Calif., Nov. 5, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), which pioneered the discovery and development of HuCNS-SC® cells, a proprietary population of highly purified, expandable human neural stem cells and is leading the development of cell based therapies for the treatment of disorders of the central nervous system, today reported financial results for the third quarter ended September 30,... 
Printer Friendly Version
11/03/14StemCells, Inc. to Host Inaugural Investor and Analyst Event in New York
NEWARK, Calif., Nov. 3, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), who pioneered the discovery and development of HuCNS-SC® cells, a proprietary population of highly purified, expandable human neural stem cells and is leading the development of cell based therapies for the treatment of disorders of the central nervous system, today announced that it will host its first investor and analyst event in New York, November 20, 2014. "Our Company has begun the transformation from small... 
Printer Friendly Version
10/07/14StemCells, Inc. Initiates Phase II Clinical Trial in Cervical Spinal Cord Injury
First Study Assessing Efficacy of Neural Stem Cells for the Treatment of Cervical Spinal Cord Injury NEWARK, Calif., Oct. 7, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell based therapies for the treatment of disorders of the central nervous system, announced today that it has initiated its Pathway® Study, a Phase II proof of concept clinical trial using its proprietary HuCNS-SC® platform of human neural stem cells for the treatmen... 
Printer Friendly Version
10/01/14StemCells, Inc. to Participate at the 2014 Stem Cell Meeting on the Mesa
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., Oct. 1, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will make a presentation on the Company's programs and operations at the 4th Annual Partnering Forum, part of the 2014 Stem Cell Meeting on the Mesa, to be held October 7-9. Mr. McGlynn is scheduled to speak at 3:15 p.m. Pacific Time on Tuesday, October 7, at the Estancia La Jolla... 
Printer Friendly Version
09/04/14StemCells, Inc. to Participate at the 16th Annual Rodman & Renshaw Global Investment Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., Sept. 4, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will present at the 16th Annual Rodman & Renshaw Global Investment Conference Wednesday, September 10, at 9:10 AM EDT in the Holmes II Salon room at the New York Palace Hotel, 455 Madison Avenue, New York, NY. Management is scheduled to present an update on the Company's programs, pipeline and ope... 
Printer Friendly Version
08/12/14StemCells, Inc. Reports Second Quarter 2014 Financial Results and Provides Business Update
Conference Call to Be Hosted August 12, 2014 at 4:30 p.m. EDT NEWARK, Calif., Aug. 12, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today provided a business update and reported financial results for the second quarter ended June 30, 2014. "The highlight for the quarter was the release of the first interim data from our ongoing... 
Printer Friendly Version
08/05/14StemCells, Inc. Announces Webcast to Discuss Second Quarter 2014 Financial Results
NEWARK, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the second quarter ended June 30, 2014 after the market close on Tuesday, August 12. StemCells will host a conference call and webcast to discuss its results and an update on its business at 1:30 p.m. Pacif... 
Printer Friendly Version
07/18/14StemCells, Inc. Announces Closing of $20 Million Offering
NEWARK, Calif., July 18, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), today announced that it has closed its previously announced offering of common stock and short term warrants. The Company sold a total of 11,299,435 units to two well recognized institutional biotechnology investors and received total proceeds, net of offering expenses and placement agent fees, of approximately $18.7 million. Each unit consists of one share of common stock and a warrant to purchase 0.85 of a share o... 
Printer Friendly Version
07/15/14StemCells, Inc. Announces Proposed $20 Million Offering
NEWARK, Calif., July 15, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), today announced its intent to offer and sell 11,299,435 shares of common stock and short term warrants for the purchase of up to 9,604,520 additional shares of common stock to two well recognized institutional biotechnology investors, subject to market and other conditions, for gross proceeds of $20 million, before deducting placement fees and other offering expenses. StemCells intends to use the net proceeds of the... 
Printer Friendly Version
07/07/14StemCells, Inc. Appoints Dr. Alan Trounson to Board of Directors
NEWARK, Calif., July 7, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today the appointment of Alan Trounson, Ph.D. to its Board of Directors. Dr. Trounson most recently served as President of The California Institute of Regenerative Medicine (CIRM), the largest scientific funding body for stem cell research in the world. "We are thrilled to welcome Dr. Trounson to our Board," said Martin McGlynn, president and CEO of StemCells, Inc. "His diverse background includes ground... 
Printer Friendly Version
06/23/14StemCells, Inc. President and CEO Martin McGlynn to Present on a Regenerative Medicine Panel at the 2014 BIO International Convention
NEWARK, Calif., June 23, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will be a panelist at the 2014 BIO International Convention on June 25, 2014 at 4:15 pm PDT. Mr. McGlynn will participate in the panel discussion, "How International Collaboration is Accelerating the Field." This panel will showcase examples of international collaboration that are producing results or initiating new approaches to cross-border research. Under Mr. M... 
Printer Friendly Version
06/20/14StemCells, Inc. Announces Closure of Enrollment in Phase I/II Dry Age-Related Macular Degeneration Trial
Phase II Clinical Trial to Begin This Year NEWARK, Calif., June 20, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) yesterday announced that based on positive interim results, it has closed enrollment in its Phase I/II clinical trial for dry age-related macular degeneration (AMD) in order to focus its efforts on a follow-on Phase II randomized, controlled proof-of-concept study, later this year. Interim results for the current AMD trial show a 70 percent reduction in the rate of geograph... 
Printer Friendly Version
06/19/14StemCells, Inc. Interim Results Show Improvement in Visual Function and Slowing of Disease Progression in Phase I/II Dry AMD Trial
Company to Host Webcast to Discuss Interim Data Today NEWARK, Calif., June 19, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) reported positive interim results from its Phase I/II clinical trial of the Company's proprietary HuCNS-SC® human neural stem cell platform in dry age-related macular degeneration (AMD) yesterday evening at the 12th annual meeting of the International Society for Stem Cell Research (ISSCR) in Vancouver, Canada. Interim trial results show a 65 percent redu... 
Printer Friendly Version
06/17/14StemCells, Inc. Strengthens Senior Executive Team
NEWARK, Calif., June 17, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today one promotion and three new appointments to the Company's executive team. Stephen Huhn, M.D., F.A.C.S., F.A.A.P. has been promoted to the newly created position of vice president, CNS clinical research and chief medical officer. Joel Naor, M.D., M.B.A., M.Sc., has joined StemCells, Inc. as vice president, clinical development, ophthalmology, and will report to Dr. Stephen Huhn; Naymisha Patel has join... 
Printer Friendly Version
05/29/14StemCells, Inc. to Participate at the 4th LD Micro Invitational Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., May 29, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will present at the 4th LD Micro Invitational Conference, on Wednesday, June 4, at 11:30 AM PDT at the Luxe Hotel, 11461 Sunset Boulevard, in Los Angeles. Management is scheduled to present an update on the Company's programs, pipeline and operations. A live webcast of the presentation will be avai... 
Printer Friendly Version
05/29/14StemCells, Inc. Posts Letter to Shareholders
NEWARK, Calif., May 29, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, posted today the following Letter to Shareholders from its President and CEO, Martin McGlynn. Dear Fellow Shareholders, As I mentioned in my last letter to shareholders, the pace of development at StemCells, Inc. has been accelerating quickly, so it is especially important to have regular updates ... 
Printer Friendly Version
05/22/14StemCells, Inc. Advances Clinical Trial in Age-Related Macular Degeneration to Final Cohort
Phase I/II AMD Trial on Track to Complete Enrollment in June NEWARK, Calif., May 22, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that it has transplanted the Company's proprietary HuCNS-SC® (purified human neural stem cells) into the first five patients in the final cohort of its 16-patient Phase I/II trial for geographic atrophy of age related macular degeneration (GA-AMD). Each of the eight patients in this second cohort will receive a dose of 1 million stem cel... 
Printer Friendly Version
05/19/14StemCells, Inc. Provides Update on Its Phase I/II Study in Spinal Cord Injury
Significant Sensory Gains Observed in Additional Patients NEWARK, Calif., May 19, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Armin Curt, M.D., study principal investigator, presented an interim update on the Phase I/II trial in spinal cord injury at the Annual Meeting of the American Spinal Injury Association in San Antonio, Texas. Interim analysis of clinical data to date has shown that the significant post-transplant gains in sensory function first reported in... 
Printer Friendly Version
05/14/14StemCells, Inc. Reports First Quarter 2014 Financial Results and Provides Business Update
Conference Call to be Hosted May 14, 2014 at 4:30 p.m. EDT NEWARK, Calif., May 14, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today provided a business update and reported financial results for the first quarter ended March 31, 2014. "We have made substantial progress in our clinical programs this past quarter," said Martin M... 
Printer Friendly Version
05/01/14StemCells, Inc. Announces Webcast to Discuss First Quarter 2014 Financial Results
NEWARK, Calif., May 1, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the first quarter ended March 31, 2014 after the market close on Wednesday, May 14. StemCells will host a conference call and webcast to discuss its results and an update on its business at 1:30 p.m. Pacific... 
Printer Friendly Version
04/17/14StemCells, Inc. Completes Enrollment in Spinal Cord Injury Trial
Interim Data to be Presented at Upcoming American Spinal Injury Association Conference NEWARK, Calif., April 17, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that it has completed enrollment in the Company's Phase I/II clinical trial in spinal cord injury. The multi-national, open-label, Phase I/II trial is evaluating both safety and preliminary efficacy of StemCells, Inc.'s proprietary HuCNS-SC® human neural stem cells as a treatment for chronic spinal cord injury. Th... 
Printer Friendly Version
03/19/14StemCells, Inc. to Participate at the 13th Annual Needham Healthcare Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., March 19, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will present at the 13th Annual Needham Healthcare Conference, on Wednesday, April 9, at 8:40 AM EDT at the Westin Grand Central Hotel, 212 East 42nd Street, in New York City. Management is scheduled to present an update on the Company's programs, pipeline and operations. A live webcast of the pr... 
Printer Friendly Version
03/12/14StemCells, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Business Update
Conference Call to be Hosted March 12, 2014 at 4:30 p.m. EDT NEWARK, Calif., March 12, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2013. "2013 was a year of significant clinical and regulatory progress for StemCel... 
Printer Friendly Version
03/10/14StemCells, Inc. to Participate at 2014 Regen Med Investor Day in New York
President and CEO Martin McGlynn Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., March 10, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Martin McGlynn will present at the 2nd Annual Regen Med Investor Day, Wednesday, March 26, 2014, at 3:30 pm EDT at the Metropolitan Club, One East 60th Street, in New York City. Mr. McGlynn is scheduled to present an update on the Company's programs, pipeline and operations. Organized ... 
Printer Friendly Version
03/05/14StemCells, Inc. Announces Webcast to Discuss Fourth Quarter and Full Year 2013 Financial Results
NEWARK, Calif., March 5, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the fourth quarter and full year ended December 31, 2013 after the market close on Wednesday, March 12. StemCells will host a conference call and webcast to discuss its results and an update on its busines... 
Printer Friendly Version
02/12/14StemCells, Inc. Announces Completion of the First of Two Cohorts in its Dry Age-Related Macular Degeneration Trial
NEWARK, Calif., Feb. 12, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that it has completed enrollment of the first of two planned patient cohorts in the Company's clinical trial of its proprietary HuCNS-SC® product candidate (purified human neural stem cells) for dry age-related macular degeneration (AMD). This cohort consisted of eight subjects, four of whom each received 200,000 cells and four of whom each received 1,000,000 cells. The last patient in this cohort was... 
Printer Friendly Version
01/30/14StemCells, Inc. Announces Presentation at Two Upcoming Investor Conferences
President and CEO Martin McGlynn Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., Jan. 30, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Martin McGlynn will present at the following conferences: 16th Annual BIO CEO & Investor Conference in New York on February 10, 2014, at 2:30 p.m. EST Leerink Swann 2014 Global Healthcare Conference in New York on February 12, 2014 at 3:00 p.m. EST As Martin McGlynn,... 
Printer Friendly Version
01/13/14StemCells, Inc. Technology is Featured in Canadian TV Broadcast
In an Extended Segment Dr. Michael Fehlings Discusses the Importance of This Technology in Spinal Cord Injury NEWARK, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that its technology was featured January 10 in a television segment which aired at 10 PM on CTV News Channel and 11 PM on the CTV National News. The story, titled 'Start of stem-cell study offers hope to patients with spinal cord injuries,' includes an interview with the first subject being t... 
Printer Friendly Version
01/10/14StemCells, Inc. Expands Phase I/II Spinal Cord Injury Trial to North America
First Subject in Canada Transplanted at the University of Calgary NEWARK, Calif., Jan. 10, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that a team at the University of Calgary successfully transplanted its first subject in the Company's Phase I/II clinical trial in chronic spinal cord injury, with the Company's proprietary HuCNS-SC® human neural stem cells. The ninth subject to enroll in the trial, which was initiated in Switzerland, is the first spinal cord injury pa... 
Printer Friendly Version
01/07/14StemCells, Inc. to Discuss Plans for Advancing Clinical Studies in Spinal Cord Injury and Age Related Macular Regeneration
Company to Present at 2014 Alliance for Regenerative Medicine State of the Industry Briefing NEWARK, Calif., Jan. 7, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Eliseo Salinas, M.D., Executive Vice President and Head of Research and Development, will provide an update on the StemCells, Inc. development programs and translational work being done with the Company's proprietary HuCNS-SC® human neural stem cells, at the 2014 Alliance for Regenerative Medicine (ARM) S... 
Printer Friendly Version
01/06/14StemCells, Inc. Posts Letter to Shareholders
NEWARK, Calif., Jan. 6, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, posted today the following Letter to Shareholders from its President and CEO, Martin McGlynn. Dear Fellow Shareholders, Every day, the news media brings us word of some new advancement in the development of stem cell therapies. While you clearly comprehend the vast potential of stem cell therapeut... 
Printer Friendly Version
11/14/13StemCells, Inc. Appoints Greg Schiffman as Chief Financial Officer
NEWARK, Calif., Nov. 14, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, today announced that Greg Schiffman will join its executive team as Chief Financial Officer and Executive Vice President of Finance, effective January 1, 2014. In his new role, Mr. Schiffman will be responsible for all aspects of the Company's financing activities, financial reporting and controls, corpo... 
Printer Friendly Version
11/05/13StemCells, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
NEWARK, Calif., Nov. 5, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results for the third quarter ended September 30, 2013 and provided a business update. "In the third quarter, we made solid progress executing the clinical development plan for our proprietary HuCNS-SC® cells by actively recruiting more... 
Printer Friendly Version
10/31/13StemCells, Inc. Announces Webcast to Discuss Third Quarter 2013 Financial Results and Business Update
NEWARK, Calif., Oct. 31, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the third quarter ended September 30, 2013 after the market close on Tuesday, November 5. In connection with this announcement, StemCells will host a conference call and webcast to discuss its results and ... 
Printer Friendly Version
10/29/13StemCells, Inc. Acquires Seminal Neural Stem Cell Patent Portfolio
NEWARK, Calif., Oct. 29, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the acquisition of a portfolio of issued US and Canadian patents to which it had previously held an exclusive worldwide license. The portfolio broadly claims the manufacture and proliferation of purified populations of human neural stem cells and their use as therapeutics and as tools for drug discovery. The acquisition relieves the Company of all milestone and royalty obligations under the license ag... 
Printer Friendly Version
10/22/13StemCells, Inc. to Present at Leading Conference on Neuroregeneration in Barcelona
NEWARK, Calif., Oct. 22, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), the leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, announced today that Ann Tsukamoto, Ph.D., Executive Vice President, Scientific and Strategic Alliances at StemCells, will speak at the B-Debate International Center for Scientific Debate Barcelona,to be held October 23-24 in Barcelona, Spain. Dr. Tsukamoto will participate on October 23 in the forum "... 
Printer Friendly Version
10/21/13StemCells, Inc. Announces Results of Long-Term Follow-Up Study in Batten Disease
Human Clinical Data Encompasses Five Years of Post-Transplant Safety NEWARK, Calif., Oct. 21, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today the results of a four-year observation study in patients with neuronal ceroid lipofuscinosis (NCL), also referred to as Batten disease, who had been transplanted with the Company's proprietary HuCNS-SC® cells (purified human neural stem cells) in the initial Phase I study. Key results include long-term evidence of safety, up to five... 
Printer Friendly Version
10/17/13StemCells, Inc. Announces Investigators From Two Clinical Trials to Present at Congress of Neurological Surgeons Annual Meeting
NEWARK, Calif., Oct. 17, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), the leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, announced today that investigators from two of the Company's clinical trials will make presentations at the Congress of Neurological Surgeons Annual Meeting, which will be held October 19-23 at the Moscone West Convention Center in San Francisco, California. The first presentation, scheduled for 2:... 
Printer Friendly Version
10/10/13StemCells, Inc. Executive Vice President Ann Tsukamoto, Ph.D., to Make Keynote Address at 2013 Stem Cell Meeting on the Mesa's Scientific Symposium
NEWARK, Calif., Oct. 10, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), the leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, announced today that Ann Tsukamoto, Ph.D., Executive Vice President, Scientific and Strategic Alliances at StemCells, will make the keynote address at the Scientific Symposium of the 2013 Stem Cell Meeting on the Mesa, to be held October 14-16 in La Jolla, Calif. In her address, "Human Neural Stem Cell... 
Printer Friendly Version
10/09/13StemCells, Inc. to Present at 2013 Stem Cell Meeting on the Mesa's Regen Med Partnering Forum
NEWARK, Calif., Oct. 9, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), the leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, announced today that President and CEO Martin McGlynn will make a presentation on the Company's programs and operations at the Regen Med Partnering Forum during the 2013 Stem Cell Meeting on the Mesa, to be held October 14-16. Mr. McGlynn is scheduled to speak at 11:00 a.m. Pacific Time on Monday, Octob... 
Printer Friendly Version
10/08/13StemCells, Inc. Announces Closing of $18.6 Million Public Offering
Terminates $30 Million Equity Purchase Agreement With Lincoln Park Capital NEWARK, Calif., Oct. 8, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it has closed its previously announced underwritten public offering of common stock and warrants. The Company sold a total of 12,845,500 units, which includes the underwriter's full over-allotment option. The Company sold the units at a public offering price of $1.45 per unit and received total proceeds, net of offering ex... 
Printer Friendly Version
10/02/13StemCells, Inc. Receives FDA Authorization of IND for Spinal Cord Injury
NEWARK, Calif., Oct. 2, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that the U.S. Food and Drug Administration (FDA) has authorized the Company's Investigational New Drug (IND) application for clinical testing of the Company's proprietary HuCNS-SC® human neural stem cells as a treatment for spinal cord injury. As a first action under this IND, the Company is working to open U.S. sites for its Phase I/II clinical trial for chronic spinal cord injury, which is currently ... 
Printer Friendly Version
10/02/13StemCells, Inc. Announces Pricing of Public Offering to Raise $16.2 Million
NEWARK, Calif., Oct. 2, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the pricing of an underwritten public offering of an aggregate of 11,170,000 units at a public offering price of $1.45 per unit. Each unit consists of one share of common stock, par value $.01 per share, and a warrant to purchase one half share of common stock. The warrants have an exercise price of $1.80 per share, are exercisable immediately, and will expire five years from the date of issuance. The ... 
Printer Friendly Version
10/01/13StemCells, Inc. Annoucnes Proposed Public Offering of Common Stock and Warrants
NEWARK, Calif., Oct. 1, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritten public offering. The shares and warrants are being offered under the Company's effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). StemCells intends to use the net proceeds of the offering for general corporate purposes, including... 
Printer Friendly Version
09/18/13StemCells, Inc. Announces New Preclinical Data Showing HuCNS-SC(R) Cells Preserve Visual Function by Keeping Photoreceptors Normal and Healthy
NEWARK, Calif., Sept. 18, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the publication of preclinical data confirming that the Company's proprietary HuCNS-SC cells (purified human neural stem cells) preserve photoreceptor cells and visual function in a widely used model of retinal degeneration. The data show not only that HuCNS-SC cells preserve the number of photoreceptors that would otherwise be lost, but also that the surviving photoreceptors appear healthy and norma... 
Printer Friendly Version
09/12/13Stemcells, Inc. Announces First High-Dose Patient Transplanted in Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration
FDA Authorizes Expansion to Five Trial Sites in the United States NEWARK, Calif., Sept. 12, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced dosing of the first high-dose patient in the Company's Phase I/II clinical trial in dry age-related macular degeneration (AMD). The patient, the fifth overall in the 16-patient trial, was transplanted yesterday with one million HuCNS-SC® cells (purified human neural stem cells). The first four patients each received a dose of 200,000 ... 
Printer Friendly Version
09/09/13StemCells, Inc. Publishes Comprehensive Review of Results From HuCNS-SC Clinical Trials
NEWARK, Calif., Sept. 9, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the publication of a comprehensive overview describing the therapeutic potential and results from early clinical trials of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells). The paper was published recently in Stem Cell Research & Therapy, an international peer-reviewed journal considered to be the major forum for translational research into stem cell therapi... 
Printer Friendly Version
08/07/13StemCells, Inc. Reports Second Quarter 2013 Financial Results and Provides Business Update
NEWARK, Calif., Aug. 7, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results for the second quarter ended June 30, 2013, and provided a business update. "The data emerging from our clinical trials, including the two-year Pelizeaus-Merzbacher disease (PMD) data announced last week, continue to build our c... 
Printer Friendly Version
08/05/13StemCells, Inc. Announces Webcast to Discuss Second Quarter 2013 Financial Results and Business Update
NEWARK, Calif., Aug. 5, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the second quarter ended June 30, 2013 after the market close on Wednesday, August 7. In connection with this announcement, StemCells will host a conference call and webcast to discuss its results and an up... 
Printer Friendly Version
08/02/13StemCells, Inc. Presents Two-Year Pelizaeus-Merzbacher Disease (PMD) Data Suggesting Departure From Natural History of the Disease
NEWARK, Calif., Aug. 2, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today presented data which show that two years after transplantation of the Company's proprietary HuCNS-SC® cells (purified human neural stem cells) into patients with Pelizaeus-Merzbacher disease (PMD), the evidence of myelination, by magnetic resonance imaging (MRI), is more pronounced compared to one year post-transplantation, the gains in neurological function reported after one year were maintained, and there wer... 
Printer Friendly Version
07/30/13StemCells, Inc. Launches Alzheimer's Disease Program Supported by California Institute for Regenerative Medicine
Company Has Received First Disbursement of $3.8 Million NEWARK, Calif., July 30, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it has formally launched its Alzheimer's disease program, which is being supported by the California Institute for Regenerative Medicine (CIRM). The goal of the project is to file, within four years, an Investigational New Drug (IND) application with the U.S. Food and Drug Administration to evaluate the Company's proprietary HuCNS-SC® produ... 
Printer Friendly Version
07/01/13StemCells, Inc. Added to Russell Microcap Index
NEWARK, Calif., July 1, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced its addition to the Russell Microcap Index following Russell Investments' reconstitution of its comprehensive set of U.S. and global equity indexes. The Russell Microcap Index measures the performance of the microcap segment of the U.S. equity market. Microcap stocks make up less than 3 percent of the U.S. equity market (by market cap) and consist of the smallest 1,000 securities in the small-cap Russe... 
Printer Friendly Version
06/10/13StemCells, Inc. Strengthens Product Development Team and Appoints Executive to Focus on Scientific and Strategic Alliances
NEWARK, Calif., June 10, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced key hires to strengthen its product development capabilities and announced the creation of a new corporate function responsible for establishing scientific and strategic alliances and for building on the Company's existing stem cell technology platform.   Eliseo Salinas, M.D., has joined the Company as Executive Vice President and Head of Research and Development, and will be responsible for the... 
Printer Friendly Version
06/04/13StemCells, Inc. Secures $30 Million Financing Commitment From Lincoln Park Capital
Includes Initial $3 Million Investment NEWARK, Calif., June 4, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, has entered into an agreement with Lincoln Park Capital Fund, LLC ("Lincoln Park"), an institutional investor based in Chicago, Illinois, under which the Company has the right to sell up to $30.0 million of common stock to Li... 
Printer Friendly Version
06/03/13StemCells, Inc.'s Spinal Cord Injury Trial Approved by Health Canada
Trial Open to Patients With Complete or Incomplete Injury NEWARK, Calif., June 3, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that Health Canada has authorized the Company to expand its Phase I/II clinical trial for chronic spinal cord injury into Canada. The Phase I/II trial,  currently underway in Zurich, Switzerland, is designed to evaluate the safety and preliminary efficacy of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells... 
Printer Friendly Version
05/09/13StemCells, Inc. Reports First Quarter 2013 Financial Results and Provides Business Update
NEWARK, Calif., May 9, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results for the first quarter ended March 31, 2013 and provided a business update. "In the first quarter, we reported the most recent data from our spinal cord injury trial, which showed that the multi-segmental gains in sensory function... 
Printer Friendly Version
05/07/13StemCells, Inc. Announces Webcast to Discuss First Quarter 2013 Financial Results and Business Update
NEWARK, Calif., May 7, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the first quarter ended March 31, 2013 after the market close on Thursday, May 9. In connection with this announcement, StemCells will host a conference call and webcast to discuss its results and an update ... 
Printer Friendly Version
04/18/13StemCells, Inc. Adds Byers Eye Institute at Stanford as Second Site for Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration
NEWARK, Calif., April 18, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the addition of the Byers Eye Institute at Stanford, located in Palo Alto, Calif., as a second site for the Company's Phase I/II clinical trial of its proprietary HuCNS-SC® product candidate (purified human neural stem cells) in dry age-related macular degeneration (AMD). AMD is the leading cause of vision loss and blindness in people over 55 years of age, and approximately 30 million people worldwid... 
Printer Friendly Version
04/15/13StemCells, Inc. to Participate at 2013 Regen Med Investor Day in New York
NEWARK, Calif., April 15, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will present an update on the Company's programs and operations at the 2013 Regen Med Investor Day to be held on Wednesday, April 17, 2013, at the Harmonie Club, 4 East 60th Street, New York, NY. Mr. McGlynn is scheduled to make his presentation at 4:00 pm EDT. In addition, Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc... 
Printer Friendly Version
04/11/13StemCells, Inc. Enters Agreement to Receive $19.3 Million From California Institute for Regenerative Medicine to Help Fund IND for Alzheimer's Disease
NEWARK, Calif., April 11, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it has entered into an agreement with the California Institute for Regenerative Medicine (CIRM) under which CIRM will provide approximately $19.3 million to help fund preclinical development and IND-enabling activities of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) for Alzheimer's disease. The funding, which will be in the form of a forgivable loan, w... 
Printer Friendly Version
04/09/13CORRECTION -- StemCells, Inc. Closes $10 Million Debt Financing
NEWARK, Calif., April 9, 2013 (GLOBE NEWSWIRE) -- In a press release issued under the same headline earlier today by StemCells, Inc. (Nasdaq:STEM), please note that in the first paragraph of the release, the pro forma cash balance date should be December 31, 2012, not December 31, 2013. All other data was correct. CONTACT: Rodney Young StemCells, Inc. Chief Financial Officer (510) 456-4128 Ian Stone Russo Partners (619) 308-6541 ... 
Printer Friendly Version
04/09/13StemCells, Inc. Closes $10 Million Debt Financing
NEWARK, Calif., April 9, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it has closed a $10 million debt financing from Silicon Valley Bank (SVB). The loan funds will be used for general corporate purposes, and increase the Company's December 31, 2013 pro forma cash balance to $34.4 million. This total also includes $2.0 million in net proceeds received subsequent to the end of the year from the exercise of warrants and the sale of shares of common stock. "We are... 
Printer Friendly Version
03/20/13StemCells, Inc. Expands Patent Portfolio
NEWARK, Calif., March 20, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it has acquired from NsGene A/S, a privately held Danish biotechnology company, a patent family claiming GFAP+ Nestin+ cells, including U.S. Patent Nos. 6,878,543 and 7,303,912 and European patent application 00973148. GFAP and Nestin are proteins that are co-expressed by certain key cells found in the human central nervous system. Each patent claims a cell culture of undifferentiated GFAP+ Nest... 
Printer Friendly Version
03/19/13StemCells, Inc. Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Business Update
NEWARK, Calif., March 19, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2012. "2012 was an eventful and positive year for StemCells, Inc.," said Martin McGlynn, President and CEO of StemCells, Inc. "We published a br... 
Printer Friendly Version
02/12/13StemCells, Inc. Announces First Patient Cohort Completes Spinal Cord Injury Trial - Gains in Sensory Function Persist 12 Months After Stem Cell Transplant
Improvement From Complete to Incomplete Injury Observed in One Patient NEWARK, Calif., Feb. 12, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that the twelve-month data from the first patient cohort in the Company's Phase I/II clinical trial of its proprietary HuCNS-SC® product candidate (purified human neural stem cells) for chronic spinal cord injury continued to demonstrate a favorable safety profile, and showed that the considerable gains in sensory function observe... 
Printer Friendly Version
02/06/13StemCells, Inc. to Present at 2013 BIO CEO & Investor Conference
NEWARK, Calif., Feb. 6, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will present an update on the Company's programs and operations at the 15th Annual BIO CEO & Investor Conference to be held February 11-12 in New York City. Mr. McGlynn is scheduled to speak at 8:30 a.m. Eastern Time on Tuesday, February 12. A live webcast of the presentation will be available through the Company's corporate website at http://investor.stemc... 
Printer Friendly Version
01/23/13StemCells, Inc. to Present at Phacilitate Cell & Gene Therapy Forum
NEWARK, Calif., Jan. 23, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Ann Tsukamoto, Ph.D., Executive Vice President, Research and Development, will make a presentation on the Company's clinical development programs at the Phacilitate Cell & Gene Therapy Forum to be held January 28-30, in Washington, DC. Dr. Tsukamoto is scheduled to speak at 12:25 p.m. ET on Wednesday, January 30, as part of the session on "Clinical development updates from leading cell and ge... 
Printer Friendly Version
11/29/12StemCells, Inc. to Present at 2012 World Stem Cell Summit
NEWARK, Calif., Nov. 29, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Ann Tsukamoto, Ph.D., Executive Vice President, Research and Development, will make a presentation on the Company's clinical development programs at the 2012 World Stem Cell Summit to be held December 3-5 at the Palm Beach County Convention Center, West Palm Beach, Florida. Dr. Tsukamoto is scheduled to speak during the Clinical Trial Update session to be held 10:30 a.m. to 12:00 p.m. Eastern Tim... 
Printer Friendly Version
11/08/12StemCells, Inc. Reports Third Quarter 2012 Financial Results and Provides Business Update
NEWARK, Calif., Nov. 8, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results for the third quarter ended September 30, 2012 and provided a business update. "We remain committed to building shareholder value by generating meaningful preclinical and clinical data in a cash-efficient manner," said Martin Mc... 
Printer Friendly Version
11/05/12StemCells, Inc. Announces Webcast to Discuss Third Quarter 2012 Financial Results and Business Update
NEWARK, Calif., Nov. 5, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the third quarter ended September 30, 2012 after the market close on Thursday, November 8. In connection with this announcement, StemCells will host a conference call and webcast to discuss its results and ... 
Printer Friendly Version
10/30/12StemCells, Inc. Partners With R Biomedical to Develop and Commercialize Reagents for Human iPS Cell Research
Announces Launch of "Ultra-Primary" SC Proven(R) Human Fibroblast Cell Line NEWARK, Calif., Oct. 30, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that it has partnered with R Biomedical, an Edinburgh, UK-based biomedical company, to develop and commercialize a range of cell lines and reagents to facilitate human induced pluripotent stem (iPS) cell-based research for regenerative medicine applications. The first product under the partnership, an "ultra-primary" human fi... 
Printer Friendly Version
10/26/12StemCells, Inc. to Present at 2012 Stem Cell Meeting on the Mesa's Investor and Partnering Forum
NEWARK, Calif., Oct. 26, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will make a presentation on the Company's programs and operations at the 2nd Annual Investor and Partnering Forum during the 2012 Stem Cell Meeting on the Mesa to be held October 29 -31. Mr. McGlynn is scheduled to speak at 10:15 a.m. Pacific Time on Tuesday, October 30, at the Sanford Consortium for Regenerative Medicine in La Jolla, California. The Stem Cell... 
Printer Friendly Version
10/18/12StemCells, Inc. Adds Eliseo Salinas to Advise on Product Development Strategy for Its Proprietary Human Neural Stem Cells
Experienced and Successful Senior Executive With Global CNS Drug Development Expertise NEWARK, Calif., Oct. 18, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced it has retained Eliseo Oreste Salinas, MD, MSc, on an exclusive basis, to help formulate and execute the clinical translation and product development strategy for the Company's proprietary HuCNS-SC® cells (purified human neural stem cells). Dr. Salinas was most recently Executive Vice President, Head of Development... 
Printer Friendly Version
10/17/12Ascendiant Capital Markets Initiates Research Coverage of StemCells, Inc. With Buy Recommendation
NEWARK, Calif., Oct. 17, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Ascendiant Capital Markets, LLC initiated independent research coverage on the Company with a "Buy" recommendation. The report was authored by Keay Nakae, CFA, Senior Research Analyst – Healthcare, at Ascendiant Capital. Ascendiant Capital Markets, LLC, is a full-service investment banking, equity research, market making and securities trading firm focused on small-cap and micro-cap public co... 
Printer Friendly Version
10/16/12StemCells, Inc. Launches Four New Human Neural Stem Cell Kits Under SC Proven(R) Brand
NEWARK, Calif., Oct. 16, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today the launch of four new SC Proven human neural stem cell (NSC) kits for use in neuroscience research. Each kit will contain high purity, multipotent NSCs derived from a different area of the human central nervous system (CNS), and will provide researchers with a reproducible and scalable serum-free platform with which to perform a broad range of assays.  With these kits, researchers will now have the a... 
Printer Friendly Version
10/12/12StemCells, Inc. Awarded Broad U.S. Patent Covering Expandable Liver Cells
Company Has Shown Cells Engraft and Have Robust Biologic Activity in the Liver NEWARK, Calif., Oct. 12, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the issuance of U.S. Patent Number 8,283,164 titled "Liver engrafting cells, assays, and uses thereof." The patent broadly covers purified populations of human liver cells, including the Company's human liver engrafting cells (hLEC). hLEC cells were first isolated by Company researchers in the late 1990s, and Company scien... 
Printer Friendly Version
10/10/12StemCells, Inc. Announces Simultaneous Publication of Preclinical and Clinical Results of Its Neural Stem Cells for Myelination Disorder
Data Show Potential for the Company's Neural Stem Cells to Treat Broad Range of Myelination Disorders NEWARK, Calif., Oct. 10, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that two papers reporting clinical and preclinical data demonstrating the therapeutic potential of the Company's proprietary HuCNS-SC® cells (purified human neural stem cells) for a range of myelination disorders were published in the Oct. 10 edition of Science Translational Medicine, the peer review... 
Printer Friendly Version
10/04/12StemCells, Inc. Announces First Transplant of Neural Stem Cells Into Patient in Clinical Trial for Dry Age-Related Macular Degeneration
NEWARK, Calif., Oct. 4, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that the first patient in its Phase I/II clinical trial in dry age-related macular degeneration (AMD) has been enrolled and transplanted. The trial is designed to evaluate the safety and preliminary efficacy of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) as a treatment for dry AMD, and the patient was transplanted with the cells yesterday at the Retina Found... 
Printer Friendly Version
09/27/12StemCells, Inc. Achieves Spinal Cord Injury Milestone With First Neural Stem Cell Transplant Into Patient With Sensory Function Below the Level of Injury
NEWARK, Calif., Sept. 27, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that the first patient with an incomplete spinal cord injury has been enrolled in the Company's Phase I/II clinical trial in chronic spinal cord injury and transplanted with the Company's proprietary HuCNS-SC® neural stem cells. The patient, a Canadian man who suffered a thoracic spinal cord injury from a sports-related accident, was administered the cells yesterday at Balgrist University Hospital, U... 
Printer Friendly Version
09/12/12StemCells, Inc. to Present at Neurodegenerative Conditions Research and Development Conference
NEWARK, Calif., Sept. 12, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will make a presentation on the Company's programs and operations at the 6th Neurodegenerative Conditions Research and Development conference. Mr. McGlynn is scheduled to speak at 11:35 a.m. Pacific Time on Friday, September 14.  The Neurodegenerative Conditions Research and Development session is part of the 2nd CNS Diseases World Summit which will be held Septe... 
Printer Friendly Version
09/10/12StemCells, Inc. Provides Additional Comments on Recent Awards From the California Institute for Regenerative Medicine
NEWARK, Calif., Sept. 10, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that Martin McGlynn, President and CEO, provided additional comments about the approval of two funding awards by the California Institute for Regenerative Medicine (CIRM).   In a letter to shareholders posted on the Company's website, Mr. McGlynn said: "On Wednesday, September 5, the CIRM's governing board (the "ICOC") doubled down on its support of the groundbreaking translational research b... 
Printer Friendly Version
09/06/12StemCells, Inc. Awarded $20 Million From the California Institute for Regenerative Medicine for Alzheimer's Disease Program
Award to Fund IND-Enabling Activities for the Company's HuCNS-SC(R) Neural Stem Cells in Alzheimer's Disease NEWARK, Calif., Sept. 6, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that the California Institute for Regenerative Medicine (CIRM) has approved an award to the Company for up to $20 million under CIRM's Disease Team Therapy Development Award program (RFA 10-05). The award is to fund preclinical development of StemCells' proprietary HuCNS-SC® product candidate ... 
Printer Friendly Version
09/03/12StemCells, Inc. Reports Positive Interim Data From Spinal Cord Injury Trial
Cells and Procedure Well Tolerated; Gains in Sensory Function Confirmed NEWARK, Calif., Sept. 3, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that interim six-month data from the first patient cohort in the Company's Phase I/II clinical trial of its proprietary HuCNS-SC® product candidate (purified human neural stem cells) for chronic spinal cord injury continues to demonstrate a favorable safety profile, and shows considerable gains in sensory function in two of the t... 
Printer Friendly Version
08/30/12StemCells, Inc. to Announce Interim Data on Spinal Cord Injury Trial at the 2012 Annual Scientific Meeting of the International Spinal Cord Society
NEWARK, Calif., Aug. 30, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that Armin Curt, MD, Professor and Chairman of the Spinal Cord Injury Center at Balgrist University Hospital, University of Zurich, and principal investigator for the Company's Phase I/II clinical trial in chronic spinal cord injury, will make an oral presentation on the progress of the trial on Monday, September 3 at the 51st Annual Scientific Meeting of the International Spinal Cord Society (ISCOS),... 
Printer Friendly Version
08/23/12Maxim Group Initiates Research Coverage of StemCells, Inc. With Buy Recommendation
NEWARK, Calif., Aug. 23, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Maxim Group LLC initiated independent research coverage on the Company with a "Buy" recommendation. The report was authored by Jason Kolbert, Senior Biotechnology Analyst at Maxim Group.    Maxim Group LLC is headquartered in New York and provides a full array of financial services including investment banking, private wealth management, institutional sales and trading, and equity research. T... 
Printer Friendly Version
08/02/12Stemcells, Inc. Reports Second Quarter 2012 Financial Results and Provides Business Update
NEWARK, Calif., Aug. 2, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results for the second quarter ended June 30, 2012 and provided a business update. "We continue to be encouraged by our progress in developing cell-based therapeutics for a broad array of disorders affecting the central nervous system,"... 
Printer Friendly Version
07/31/12StemCells, Inc. Announces Webcast to Discuss Second Quarter 2012 Financial Results and Business Update
NEWARK, Calif., July 31, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the second quarter ended June 30, 2012 after the market close on Thursday, August 2. In connection with this announcement, StemCells will host a conference call and webcast to discuss its results and an up... 
Printer Friendly Version
07/31/12StemCells, Inc. Broadens HuCNS-SC(R) Patent Portfolio With Key Patent in Japan
NEWARK, Calif., July 31, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that the Japan Patent Office has granted to the Company Patent Number 5007003, titled "Enriched Central Nervous System Stem Cell and Progenitor Cell Populations, and Methods for Identifying, Isolating and Enriching for Such Populations." The patent broadly covers the prospective isolation and enrichment of neural stem and progenitor cells using antibody selection, as well as the use of these cells to ... 
Printer Friendly Version
07/26/12StemCells, Inc. Awarded $20 Million From the California Institute for Regenerative Medicine
Award to Fund IND-Enabling Activities for the Company's HuCNS-SC® Neural Stem Cells in Cervical Spinal Cord Injury Decision on Funding Alzheimer's Program Deferred to CIRM's September Board Meeting NEWARK, Calif., July 26, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that the California Institute for Regenerative Medicine (CIRM) has approved an award to the Company and its collaborators for up to $20 million under CIRM's Disease Team Therapy Develop... 
Printer Friendly Version
07/17/12StemCells, Inc. Announces Its Human Neural Stem Cells Restore Memory in Models of Alzheimer's Disease
NEWARK, Calif., July 17, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), today announced preclinical data demonstrating that its proprietary human neural stem cells restored memory and enhanced synaptic function in two animal models relevant to Alzheimer's disease (AD). The data was presented today at the Alzheimer's Association International Conference 2012 in Vancouver, Canada.   The study results showed that transplanting the cells into a specific region of the brain, the hippocam... 
Printer Friendly Version
06/21/12StemCells, Inc. Initiates Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration
Leading Cause of Blindness in Elderly NEWARK, Calif., June 21, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced initiation of a Phase I/II clinical trial of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) in dry age-related macular degeneration (AMD) referred to as Geographic Atrophy. There are no approved treatments for dry AMD. The trial is being conducted at the Retina Foundation of the Southwest's (RFSW) Anderson Vision Rese... 
Printer Friendly Version
05/17/12StemCells, Inc. Reports Positive Interim Safety Data From Spinal Cord Injury Trial
 Trial Proceeding to Enroll Patients with Incomplete Injury NEWARK, CA (May 17, 2012) – StemCells, Inc. (Nasdaq: STEM) today announced completion of the first planned interim safety review of the Company’s Phase I/II spinal cord injury clinical trial, which indicated that the surgery, immunosuppression and the cell transplants have been well-tolerated.  The trial, which is designed to evaluate the safety and preliminary efficacy of the Company’s proprietary HuCNS-SC® cells (purified ... 
Printer Friendly Version
05/10/12StemCells, Inc. Reports First Quarter 2012 Financial Results and Provides Business Update
NEWARK, Calif., May 10, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results for the first quarter ended March 31, 2012 and provided a business update. "The first quarter of 2012 turned out to be pivotal in the Company's pursuit of cell-based therapeutics for a broad array of CNS disorders," said Martin McG... 
Printer Friendly Version
05/09/12StemCells, Inc. to Provide Progress Report on Spinal Cord Injury Trial at the Interdependence 2012 Global SCI Conference Co-Sponsored by the Rick Hansen Institute and the Rick Hansen Foundation
NEWARK, Calif., May 9, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that Armin Curt, MD, FRCPC, Professor and Chairman, Spinal Cord Injury Center at the University of Zurich, and Medical Director of the Paraplegic Center at the Balgrist University Hospital and principal investigator for the Company's Phase I/II clinical trial in chronic spinal cord injury, will provide a progress report on the trial on Thursday, May 17 at the Interdependence 2012 Global SCI Conference. ... 
Printer Friendly Version
05/07/12StemCells, Inc. Announces Webcast to Discuss First Quarter 2012 Financial Results and Business Update
NEWARK, Calif., May 7, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the first quarter ended March 31, 2012 after the market close on Thursday, May 10. In connection with this announcement, StemCells will host a conference call and webcast to discuss its results and an update... 
Printer Friendly Version
04/02/12StemCells, Inc's Milestone Clinical Trial in Pelizaeus-Merzbacher Disease Shows Evidence of Myelination Following Human Neural Stem Cell Transplantation
Trial Provides Proof-of-Concept for Cell-Based Therapy in a Myelination Disorder Company to Host Conference Call Today to Discuss Summary Results NEWARK, Calif., April 2, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced preliminary evidence of progressive and durable donor-cell derived myelination in all four patients who underwent transplantation with the Company's proprietary HuCNS-SC® cells (purified human neural stem cells) in its clinical trial for Pelizaeus... 
Printer Friendly Version
03/30/12StemCells, Inc. Announces Webcast to Discuss Pelizaeus-Merzbacher Disease Clinical Trial Results
NEWARK, Calif., March 30, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that it will host a conference call and webcast to discuss results from its Phase I clinical trial in Pelizaeus-Merzbacher Disease (PMD) on Monday, April 2, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time). A summary of the trial results will be presented on Saturday, March 31, at the 2012 European Leukodystrophy Association (ELA) Families/Scientists Meeting in Paris. The Phase I trial was complet... 
Printer Friendly Version
03/20/12StemCells, Inc. Grants genOway Exclusive License to Gene Insertion Technology for Genetically Engineered Mice
genOway to be Exclusive Source Worldwide for This Cell Manipulation Technology in Genetically Modified Mice NEWARK, Calif., March 20, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) and genOway (NYSE:ALGEN) announced today that they have entered into a license agreement under which StemCells has granted genOway a worldwide, exclusive license to StemCells' Internal Ribosome Entry Site (IRES) technology for use in the development and commercialization of genetically engineered mice. Financ... 
Printer Friendly Version
03/13/12StemCells, Inc. Reports Fourth Quarter and Year End 2011 Financial Results and Provides Business Update
.yom-art-content .gnwlistitemmarginbottom { MARGIN-BOTTOM: 10px } .yom-art-content .gnwtablebottommargin { MARGIN-BOTTOM: 10px } .yom-art-content .gnwcellpaddingleft0 { PADDING-LEFT: 0px } .yom-art-content .gnwverticalaligntop { VERTICAL-ALIGN: top } .yom-art-content .gnwtextaligncenter { TEXT-ALIGN: center } .yom-art-content .gnwcellparagraphmargin { MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px } .yom-art-content .gnwverticalalignbottom { VERTICAL-ALIGN: bottom } .yom-art-c... 
Printer Friendly Version
03/09/12StemCells, Inc. Announces Webcast to Discuss 2011 Financial Results and Business Update
NEWARK, Calif., March 9, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the fourth quarter and year ended December 31, 2011 after the market close on Tuesday, March 13. In connection with this announcement, StemCells will host a conference call and webcast to discuss its resul... 
Printer Friendly Version
03/08/12StemCells, Inc. to Present at the 24th Annual Roth Growth OC Conference
NEWARK, Calif., March 8, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Rodney Young, Chief Financial Officer, will present an update on the Company's programs and operations at the 24th Annual Roth OC Growth Stock Conference on Wednesday, March 14th at 8:30 a.m. Pacific Time in Laguna Niguel, California. Additionally, the Company will be hosting one-on-one meetings throughout the day. Institutional investors that would like to request a meeting should contact Ro... 
Printer Friendly Version
02/27/12StemCells, Inc. to Participate in Qatar International Conference on Stem Cell Science and Policy 2012
NEWARK, Calif., Feb. 27, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it will participate in the Qatar International Conference on Stem Cell Science and Policy, which is being held in Qatar from February 27 to March 1, 2012. The Company, which is the leader in development of cell-based therapeutics for central nervous system disorders, was specifically invited by the conference's sponsors, the State of Qatar and Amir of Qatar His Highness Sheikh Hamad bin Khalifa A... 
Printer Friendly Version
02/08/12StemCells, Inc. to Present at 2012 BIO CEO Investor Conference
NEWARK, Calif., Feb. 8, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will present an update on the Company's programs and operations at the 14th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference to be held February 13-14 in New York City. Mr. McGlynn is scheduled to speak at 11:00 a.m. Eastern Time on Tuesday, February 14. A live webcast of the presentation will be available through the Company's corpor... 
Printer Friendly Version
02/02/12StemCells, Inc. Receives FDA Authorization for Age-Related Macular Degeneration Clinical Trial
NEWARK, Calif., Feb. 2, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that the U.S. Food and Drug Administration (FDA) has authorized the initiation of a Phase I/II clinical trial of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) in dry age-related macular degeneration (AMD), the most common form of AMD.   AMD is the leading cause of vision loss and blindness in people over 55 years of age, and approximately 30 million peopl... 
Printer Friendly Version
01/30/12StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision
NEWARK, Calif., Jan. 30, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the publication of preclinical data demonstrating that its proprietary HuCNS-SC® cells (purified human neural stem cells) protect host photoreceptors and preserve vision in an animal model of retinal disease. The preclinical results are highly relevant to human disorders of vision loss, the most notable of which is dry age-related macular degeneration (AMD). The study is available online at http:... 
Printer Friendly Version
01/09/12StemCells, Inc. to Present at Biotech Showcase 2012
NEWARK, Calif., Jan. 9, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that Martin McGlynn, President and CEO, will present a business update at the Biotech Showcase 2012 to be held January 9-11 at the Parc 55 Wyndham Hotel in San Francisco, California. Mr. McGlynn is scheduled to speak on Tuesday, January 10, at 1:45 ... 
Printer Friendly Version
12/22/11StemCells, Inc. Announces Closing of Public Offering of Common Stock and Warrants
NEWARK, Calif., Dec. 22, 2011 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it has closed its previously announced underwritten offering of an aggregate of 8,000,000 units and 8,000,000 Series B Warrants, each to purchase one unit, at a public offering price of $1.25 per unit. The Company received total proceeds, net of underwriting discounts, of approximately $9.5 million.  The proceeds will be used for general corporate purposes, including working capital and operation... 
Printer Friendly Version
12/16/11StemCells, Inc. Announces Pricing of Public Offering to Raise Up to $20 Million
NEWARK, Calif., Dec. 16, 2011 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the pricing of an underwritten public offering of an aggregate of 8,000,000 units and 8,000,000 Series B Warrants, each to purchase one unit, at a public offering price of $1.25 per unit for gross proceeds of $10 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Each Unit consists of (i) one share of the common stock, par value $.01 per share, of t... 
Printer Friendly Version
12/15/11StemCells, Inc. Announces Proposed Public Offering of Common Stock and Warrants
NEWARK, Calif., Dec. 15, 2011 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritten public offering. The shares and warrants are being offered under the Company's effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). StemCells intends to use the net proceeds of the offering for general corporate purposes, includin... 
Printer Friendly Version
12/15/11StemCells, Inc. Completes Enrollment of First Cohort in Landmark Chronic Spinal Cord Injury Trial
Opens Enrollment to Patients in US and Canada NEWARK, Calif., Dec. 15, 2011 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that the first cohort of the Company's Phase I/II clinical trial in chronic spinal cord injury have been successfully transplanted with the Company's proprietary HuCNS-SC® neural stem cells. This landmark clinical trial has a unique design, in which patients with progressively decreasing severity of injury will be treated in three sequential cohorts. The ... 
Printer Friendly Version
11/28/11StemCells, Inc. to Present at 2011 Stem Cell Meeting on the Mesa's Investor and Partnering Forum
NEWARK, Calif., Nov 28, 2011 (GlobeNewswire via COMTEX) --StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that Martin McGlynn, President and CEO, will present a business update at the 2011 Stem Cell Meeting on the Mesa's Investor and Partnering Forum to be held November 30-December 1 at the Sanford Consortium for Regenerative Medicine Building,... 
Printer Friendly Version
11/01/11StemCells, Inc. Provides Business Update and Reports Third Quarter 2011 Financial Results
NEWARK, Calif., Nov 1, 2011 (GlobeNewswire via COMTEX) --StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today provided a business update and reported financial results for the third quarter ended September 30, 2011. "As our quarterly results show, we are making real progress in containing our expenses and cash burn, and I am pleased to report that we are... 
Printer Friendly Version
10/27/11StemCells, Inc. Announces Webcast to Discuss Third Quarter Financial Results and Business Update
NEWARK, Calif., Oct 27, 2011 (GlobeNewswire via COMTEX) --StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the third quarter ended September 30, 2011 after the market closes on Tuesday, November 1. In connection with this announcement, StemCells will host a conference call and webcast to discuss its res... 
Printer Friendly Version
09/28/11StemCells, Inc. to Feature at 2011 World Stem Cell Summit
Speakers to Address the Science, Technology and Clinical Development of the Company's Human Neural Stem Cell Platform NEWARK, Calif., Sep 28, 2011 (GlobeNewswire via COMTEX) --StemCells, Inc. (Nasdaq:STEM) announced today that three of its senior executives and a key academic research collaborator are scheduled to present at the 2011 World Stem Cell Summit scheduled for October 3-5, 2011 at the Pasadena Convention Center, Pasadena, California. The World Stem Cell Summit is the global stem cel... 
Printer Friendly Version
09/23/11StemCells, Inc. CEO Martin McGlynn Featured on Wall Street Reporter
NEWARK, Calif., Sep 23, 2011 (GlobeNewswire via COMTEX) --StemCells, Inc. (Nasdaq:STEM) announced today that its president and CEO, Martin McGlynn, is featured on the financial website www.wallstreetreporter.com. In an interview, Mr. McGlynn discussed the Company's recent dosing of the first patient in the Company's Phase I/II clinical trial in chronic spinal cord injury, the Company's efforts to develop its proprietary HuCNS-SC(R) cells for a range of central nervous system disorders, its other... 
Printer Friendly Version
09/22/11StemCells, Inc. Announces World's First Neural Stem Cell Transplant in Spinal Cord Injury Patient
NEWARK, Calif., Sep 22, 2011 (GlobeNewswire via COMTEX) --StemCells, Inc. (Nasdaq:STEM) announced today that the first patient in the Company's breakthrough Phase I/II clinical trial in chronic spinal cord injury was successfully transplanted with the Company's proprietary HuCNS-SC(R) adult neural stem cells. The stem cells were administered yesterday at Balgrist University Hospital, University of Zurich, a world leading medical center for spinal cord injury and rehabilitation. The transplant su... 
Printer Friendly Version
09/01/11StemCells, Inc. Awarded CIRM Planning Grant to Pursue Preclinical Development of HuCNS-SC Cells for Alzheimer's Disease
NEWARK, Calif., Sep 1, 2011 (GlobeNewswire via COMTEX) --StemCells, Inc. (Nasdaq:STEM) announced today that the California Institute of Regenerative Medicine (CIRM) has approved the Company's application for a "Disease Team Therapy Development Planning Award." The grant, totaling approximately $100,000, will help fund the Company's plans to develop its proprietary human neural stem cell product, HuCNS-SC(R) cells, in Alzheimer's disease by enabling the Company and its collaborators at the Univer... 
Printer Friendly Version
08/26/11Roth Capital Partners Initiates Research Coverage of StemCells, Inc. With Buy Recommendation
NEWARK, Calif., Aug 26, 2011 (GlobeNewswire via COMTEX) --StemCells, Inc. (Nasdaq:STEM) announced today that Roth Capital Partners initiated independent research coverage on the Company with a "Buy" recommendation and a price target of $5.00 per share. The report was authored by Joseph Pantginis, Ph.D., senior research analyst covering life sciences and biotechnology at Roth Capital. Roth Capital is an investment banking firm dedicated to the small-cap public market. StemCells, Inc. does no... 
Printer Friendly Version
07/28/11StemCells, Inc. Reports Second Quarter Financial Results
NEWARK, Calif., Jul 28, 2011 (GlobeNewswire via COMTEX) --StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results for the second quarter ended June 30, 2011. "The Company's management and Board of Directors remain keenly focused on the successful execution of three key business objectives, namely the timely generation of clinical ... 
Printer Friendly Version
07/25/11Stemcells, Inc. Announces Webcast to Discuss Second Quarter Financial Results and Business Update
Newark, Calif., July 25, 2011 – StemCells, Inc. (NASDAQ: STEMD), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the second quarter ended June 30, 2011 after the market closes on Thursday, July 28.  In connection with this announcement, StemCells will host a conference call and webcast to discuss its results and an ... 
Printer Friendly Version
07/22/11New Publication Validates Stemcells, Inc.’s SC Proven® Reagents For Automated Production and Cell-Based Screening
Newark, Calif., July 22, 2011 – StemCells, Inc. (NASDAQ: STEMD) announced today publication of a collaborative study which used commercially available SC Proven serum-free cell culture media for the reproducible and robust production of large numbers of genetically stable, self-renewing cells that retain true multi-potent biological function over extended culture periods. This work overcomes a key hurdle to the use of non-immortalized cells for regenerative medicine, and demonstrate... 
Printer Friendly Version
07/21/11Stemcells, Inc. Regains Compliance For Continued Nasdaq Global Market Listing
NEWARK, Calif., July 21, 2011 – StemCells, Inc. (NASDAQ: STEMD), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it has received notification from The NASDAQ Stock Market that the Company has regained compliance with the minimum bid price requirement.  In order to continue listing on the NASDAQ Global Market, the NASDAQ Listing Rules require the Company... 
Printer Friendly Version
07/18/11StemCells, Inc. Relocates Corporate Headquarters and U.S. Research Labs
NEWARK, Calif., Jul 18, 2011 (GlobeNewswire via COMTEX) -- StemCells, Inc. (Nasdaq:STEM) announced today that it has relocated its corporate headquarters and U.S.-based research and development operations to 7707 Gateway Blvd, Newark, CA 94560, USA. The new facilities comprise newly constructed, custom designed laboratory and office space, and will house the majority of the Company's U.S. workforce. The Company's new main telephone number is (510) 456-4000. "This is a 'win win' situation for ... 
Printer Friendly Version
07/01/11StemCells, Inc. Announces Reverse Stock Split
PALO ALTO, Calif., Jul 1, 2011 (GlobeNewswire via COMTEX) -- StemCells, Inc. (Nasdaq:STEM) today announced that it will effect a one-for-ten reverse stock split at 12:01am on July 6, 2011. The Company anticipates that its common stock will begin trading on a split adjusted basis on The NASDAQ Global Market at the opening of trading on July 6, 2011. "In deciding to proceed with the reverse stock split, our Board of Directors considered several factors, including the NASDAQ continued listing re... 
Printer Friendly Version
06/15/11StemCells, Inc. to Present Clinical Evidence of Long-Term Survival of HuCNS-SC(R) Cells Following Completion of Immunosuppression Regimen
PALO ALTO, Calif., Jun 15, 2011 (GlobeNewswire via COMTEX) --StemCells, Inc. (Nasdaq:STEM) announced today that it will present evidence of engraftment, migration and the long-term survival of its proprietary HuCNS-SC neural stem cells following transplantation into patients with a severe neurological disorder. Importantly, the results show that the cells can persist following the completion of the planned year-long immunosuppression regimen. The data, which supports the Company's premise regard... 
Printer Friendly Version
05/04/11StemCells, Inc. Reports First Quarter Financial Results and Announces Reduction in Force
PALO ALTO, Calif., May 4, 2011 (GlobeNewswire via COMTEX) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results for the first quarter ended March 31, 2011. The Company also announced it is reducing its US-based workforce by 30 percent to reduce its cash burn rate and extend its financial resources in order to focus on advancing t... 
Printer Friendly Version
05/02/11StemCells, Inc. Announces Webcast to Discuss First Quarter Financial Results and Business Update
PALO ALTO, Calif., May 2, 2011 (GlobeNewswire via COMTEX) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the first quarter ended March 31, 2011 after the market closes on Wednesday, May 4. In connection with this announcement, StemCells will host a conference call and webcast to discuss its result... 
Printer Friendly Version
04/18/11StemCells, Inc. Advances Alzheimer's Disease Program Through Collaboration With Leading Researcher
PALO ALTO, Calif., Apr 18, 2011 (GlobeNewswire via COMTEX) -- StemCells, Inc. (Nasdaq:STEM) announced today that it has entered into a collaboration with Frank LaFerla, Ph.D., a world renowned leader in Alzheimer's disease research, to study the therapeutic potential of the Company's HuCNS-SC(R) human neural stem cells in Alzheimer's disease. Dr. LaFerla's published research has shown that mouse neural stem cells enhance memory in a mouse model of Alzheimer's disease. The goal of this collabora... 
Printer Friendly Version
04/08/11StemCells, Inc. Discontinues Batten Disease Program
PALO ALTO, Calif., Apr 8, 2011 (GlobeNewswire via COMTEX) -- StemCells, Inc. (Nasdaq:STEM) today announced that it has discontinued its Phase Ib clinical trial in neuronal ceroid lipofuscinosis (NCL, also referred to as Batten disease), a rare and fatal neurodegenerative disorder in children, due to lack of patient accrual. In 2009, the Company completed a Phase I safety trial of its HuCNS-SC(R) human neural stem cells in six patients with advanced stages of NCL at Oregon Health & Science U... 
Printer Friendly Version
03/29/11StemCells, Inc. Adds Serum-Free and Animal Component-Free Cell Culture Supplements to Its SC Proven(R) Product Portfolio
PALO ALTO, Calif., Mar 29, 2011 (GlobeNewswire via COMTEX) -- StemCells, Inc. (Nasdaq:STEM) announced today the launch of three new cell culture supplements for the derivation, culture and differentiation of human and mouse embryonic stem (ES) cells, induced pluripotent stem (iPS) cells, and tissue-derived neural stem (NS) cells.1-13 The research community demands reliable and cost-effective options for the reagents they routinely use to capture, define and instruct stem cell behavior. These ne... 
Printer Friendly Version
03/22/11StemCells, Inc. Further Expands SC Proven(R) Product Portfolio With New Line of Purified Whole Cell Lysate Reagents
PALO ALTO, Calif., Mar 22, 2011 (GlobeNewswire via COMTEX) -- StemCells, Inc. (Nasdaq:STEM) announced today the launch of nine new products and three related kits to facilitate stem cell research. The Company's new line of purified nucleic acid and protein stem cell lysate products will enable stem cell researchers to more accurately test and validate stem cell lines and associated genes and gene products. These new reagents are serum-free and are produced by purification of the DNA, RNA or pro... 
Printer Friendly Version
03/14/11StemCells, Inc. Initiates World's First Neural Stem Cell Trial in Spinal Cord Injury
PALO ALTO, Calif., Mar 14, 2011 (GlobeNewswire via COMTEX) -- StemCells, Inc. (Nasdaq:STEM) announced today the initiation of a Phase I/II clinical trial of its proprietary HuCNS-SC(R) human neural stem cells in chronic spinal cord injury. This trial is now open for enrollment, and will accrue patients with both complete and incomplete degrees of paralysis who are three to 12 months post-injury. The trial is being conducted in Switzerland at the Balgrist University Hospital, University of Zuric... 
Printer Friendly Version
03/11/11StemCells, Inc. Reports Fourth Quarter and Fiscal 2010 Financial Results and Business Highlights
PALO ALTO, Calif., Mar 11, 2011 (GlobeNewswire via COMTEX) --StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results for the fourth quarter and year ended December 31, 2010 and recent business highlights. "In 2010 we made significant progress towards achieving our business imperative of translating groundbreaking science into brea... 
Printer Friendly Version
03/08/11StemCells, Inc. to Present at ROTH Capital Partners Growth Conference
PALO ALTO, Calif., Mar 8, 2011 (GlobeNewswire via COMTEX) -- StemCells, Inc. (Nasdaq:STEM) announced today that Chief Financial Officer Rodney Young will present an update on the Company's programs and operations at the ROTH Capital Partners 23rd Annual OC Growth Stock Conference on Monday, March 14 at 5:30 p.m. Pacific Time. A live webcast of the presentation will be available through the Company's corporate website at http://www.stemcellsinc.com under the Investors section, and may also be ... 
Printer Friendly Version
02/23/11StemCells, Inc. to Present at New York Stem Cell Summit
PALO ALTO, Calif., Feb 23, 2011 (GlobeNewswire via COMTEX) -- StemCells, Inc. (Nasdaq:STEM) announced today that Martin McGlynn, President and CEO, and Stephen Huhn, M.D., Vice President and Head of CNS Program, have each been invited to speak at the 6th Annual New York Stem Cell Summit to be held March 1 at Bridgewaters in New York City. This year's Summit will feature a panel discussion on stem cell approaches to spinal cord injury, including the Company's recently authorized Phase I/II clini... 
Printer Friendly Version
02/17/11StemCells, Inc. Completes Dosing in Second Trial of HuCNS-SC(R) Neural Stem Cells
PALO ALTO, Calif., Feb 17, 2011 (GlobeNewswire via COMTEX) -- StemCells, Inc. (Nasdaq:STEM) today announced that the fourth and final patient in its Phase I clinical trial in Pelizaeus-Merzbacher Disease (PMD) has been transplanted with the Company's HuCNS-SC(R) cells (purified human neural stem cells). PMD is a fatal myelination disorder that afflicts male children. This clinical trial, which is being conducted in collaboration with UCSF Benioff Children's Hospital, is the first to evaluate ne... 
Printer Friendly Version
02/08/11StemCells, Inc. to Present at BIO CEO & Investor Conference
PALO ALTO, Calif., Feb 8, 2011 (GlobeNewswire via COMTEX) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will present an update on the Company's programs and operations at the 13th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference to be held February 14-15 in New York City. Mr. McGlynn is scheduled to speak at 1:00 p.m. Eastern Time on Tuesday, February 15. A live webcast of the presentation will be available through the Com... 
Printer Friendly Version
01/19/11StemCells, Inc. Broadens Its SC Proven(R) Product Portfolio With Launch of Two Additional Human Cell Detection Antibodies
PALO ALTO, Calif., Jan 19, 2011 (GlobeNewswire via COMTEX) -- StemCells, Inc. (Nasdaq:STEM) announced today the launch of STEM24(TM) and STEM133(TM), two new antibody reagents that have utility for the isolation and detection of a range of different human cell types. These antibodies are the latest additions to the Company's SC Proven(R) portfolio of innovative research products. "We plan to continue to expand and diversify the SC Proven portfolio with a range of products for the burgeoning st... 
Printer Friendly Version
01/11/11StemCells, Inc. Closes $10 Million Common Stock Financing
PALO ALTO, Calif., Jan 11, 2011 (GlobeNewswire via COMTEX) -- StemCells, Inc. (Nasdaq:STEM) announced today that it has closed the sale of 10 million shares of common stock, at a fixed price of $1.00 per share. The Company received total proceeds, net of offering expenses and placement agency fees, of approximately $9.4 million. The common stock was sold in a registered direct offering under the Company's effective shelf registration statement previously filed with the Securities and Exchange C... 
Printer Friendly Version
01/07/11StemCells, Inc. Announces $10 Million Common Stock Financing
PALO ALTO, Calif., Jan 7, 2011 (GlobeNewswire via COMTEX) -- StemCells, Inc. (Nasdaq:STEM) announced today that it has entered into an agreement to sell ten million shares of its common stock to selected institutional investors at a price of $1.00 per share, which represents a 10% discount to the closing price per share of January 6. The offering is expected to close today, subject to customary closing conditions, and StemCells expects to receive net proceeds, after deducting offering expenses ... 
Printer Friendly Version